Biotech makes a $303M run on Wall Street; Bil­lion­aire Thiel backs a start­up round for an­tibi­ot­ic de­vel­op­er

⇨  It’s been an­oth­er big week on the biotech IPO front. De­ci­phera $DCPH went pub­lic, rais­ing $128 mil­lion for its sol­id tu­mor work, stick­ing to the top of the range at $17 a share. The UK’s Night­star Ther­a­peu­tics $NITE team — a gene ther­a­py com­pa­ny — hit the mid­dle of the range, rais­ing $75 mil­lion at $14 a share. And Nu­Cana, an­oth­er UK biotech which jumped to Nas­daq, scored a cool $100 mil­lion from its IPO. Nu­Cana says it is work­ing on next-gen chemother­a­pies. Add it all up and you have a pic­ture of a thriv­ing biotech mar­ket, which is cer­tain to at­tract more S-1s as the in­dus­try en­joys an­oth­er up­beat run of new of­fer­ings.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.